Work

Efficacy, safety, and pharmacokinetics of alpelisib (ALP) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS): Epik-P4, a Phase II study

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-8227

Authors: Alexandra J Borst, Denise M Adams, Juan C Lopez-Gutierrez, Friedrich Kapp, Ines Vendrell, Fotis Polydoros, Elise Burmeister-Getz, Nydia Caro, Guillaume Canaud

Institutions: University of North Carolina at Chapel Hill, Children's Hospital of Philadelphia, Hospital Universitario La Paz, University of Freiburg, University Medical Center Freiburg, Novartis (Switzerland), Hôpital Necker-Enfants Malades, Université Paris Cité

Language: English

Topic: Vascular Malformations and Hemangiomas

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417015331

Cites:

Cited by: 1

Related to: